Merck to withdraw dangling accelerated approval for Keytruda in third-line stomach cancer

In a first for the dangling accelerated approvals reviewed by FDA’s oncology adcomm in April, Merck on Thursday afternoon agreed to pull a third-line stomach cancer indication for its blockbuster Keytruda after late-stage confirmatory trials failed to show clinical benefit.